BDRXBiodexa Pharmaceuticals Plcvs its industry peers
A metric-by-metric comparison of Biodexa Pharmaceuticals Plc against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BDRXThis | $566.8B#1 | — | — | — | — | — | — | — | — | — | -99.0%#5 | — |
| AXIM | — | — | — | — | 434.2%#1 | -191.7%#7 | -6961.0%#5 | — | — | — | — | — |
| AZN | — | — | — | — | 8.6%#5 | 45.3%#2 | 23.4%#1 | 21.0%#1 | — | — | 130.2%#1 | — |
| BCTX | $29M#2 | — | — | — | — | -32.7%#3 | — | — | — | — | -67.4%#3 | — |
| BCTXL | $7M#3 | — | — | — | — | -32.7%#3 | — | — | — | — | — | — |
| BCTXZ | $1M#4 | — | — | — | — | -32.7%#3 | — | — | — | — | -61.6%#2 | — |
| BDPT | — | — | — | — | 44.3%#3 | -73.3%#6 | -5701.8%#4 | — | — | — | — | — |
| BEIGF | — | — | — | — | 40.2%#4 | 144.5%#1 | 8.4%#2 | 4.9%#2 | 31.0%#1 | 7#1 | — | — |
| BGM | — | — | — | — | 51.1%#2 | -1282.1%#8 | -33.2%#3 | -5.1%#3 | — | — | -96.7%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-06.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice